US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5637616A
(en)
*
|
1993-06-18 |
1997-06-10 |
Arcturus Pharmaceutical Corporation |
Method for treating diseases mediated by proteases
|
AU1140495A
(en)
*
|
1994-01-27 |
1995-08-03 |
Bristol-Myers Squibb Company |
Method for preparing thioether conjugates
|
US6544952B1
(en)
|
1994-03-15 |
2003-04-08 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of glycoconjugates of the globo-H epitope and uses thereof
|
US6303120B1
(en)
*
|
1994-03-15 |
2001-10-16 |
Memorial Sloan-Kettering Institute For Cancer Research |
Synthesis of glycoconjugates of the lewis y epitope and uses thereof
|
US5708163A
(en)
*
|
1994-03-15 |
1998-01-13 |
Sloan-Kettering Institute Of Cancer Research |
Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
|
US6143864A
(en)
*
|
1994-06-28 |
2000-11-07 |
Merck & Co., Inc. |
Peptides
|
US5866679A
(en)
*
|
1994-06-28 |
1999-02-02 |
Merck & Co., Inc. |
Peptides
|
US5599686A
(en)
*
|
1994-06-28 |
1997-02-04 |
Merck & Co., Inc. |
Peptides
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US5907030A
(en)
*
|
1995-01-25 |
1999-05-25 |
University Of Southern California |
Method and compositions for lipidization of hydrophilic molecules
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
DE69626849T2
(de)
*
|
1995-12-22 |
2003-12-24 |
Bristol-Myers Squibb Co., Princeton |
Verzweigte hydrazongruppen enthaltende kuppler
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
SE9601158D0
(sv)
*
|
1996-03-26 |
1996-03-26 |
Stefan Svenson |
Method of producing immunogenic products and vaccines
|
DE19636889A1
(de)
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
WO1998019705A1
(en)
*
|
1996-11-05 |
1998-05-14 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
FR2766826B1
(fr)
*
|
1997-08-04 |
2001-05-18 |
Pasteur Institut |
Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
|
US6093692A
(en)
*
|
1997-09-25 |
2000-07-25 |
The University Of Southern California |
Method and compositions for lipidization of hydrophilic molecules
|
ATE490980T1
(de)
|
1998-03-19 |
2010-12-15 |
Human Genome Sciences |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
CA2338000C
(en)
*
|
1998-07-17 |
2009-12-15 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Water-soluble 4-thio-maleimido derivatives and methods for their production
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US6322980B1
(en)
*
|
1999-04-30 |
2001-11-27 |
Aclara Biosciences, Inc. |
Single nucleotide detection using degradation of a fluorescent sequence
|
US6649351B2
(en)
|
1999-04-30 |
2003-11-18 |
Aclara Biosciences, Inc. |
Methods for detecting a plurality of analytes by mass spectrometry
|
US6673550B2
(en)
|
1999-04-30 |
2004-01-06 |
Aclara Biosciences, Inc. |
Electrophoretic tag reagents comprising fluorescent compounds
|
US7001725B2
(en)
|
1999-04-30 |
2006-02-21 |
Aclara Biosciences, Inc. |
Kits employing generalized target-binding e-tag probes
|
DE19926154A1
(de)
|
1999-06-09 |
2000-12-14 |
Ktb Tumorforschungs Gmbh |
Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
|
US6706892B1
(en)
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
JP4776843B2
(ja)
|
1999-10-01 |
2011-09-21 |
イムノゲン インコーポレーティッド |
免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
|
US7771929B2
(en)
*
|
2000-04-28 |
2010-08-10 |
Monogram Biosciences, Inc. |
Tag library compounds, compositions, kits and methods of use
|
US7160735B2
(en)
*
|
2000-04-28 |
2007-01-09 |
Monogram Biosciences, Inc. |
Tagged microparticle compositions and methods
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
KR20060088905A
(ko)
|
2000-06-16 |
2006-08-07 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
면역특이적으로 BLyS에 결합하는 항체
|
CN1469735A
(zh)
*
|
2000-10-16 |
2004-01-21 |
����˹��ҩ�﹫˾ |
米托蒽醌的脂质体制剂
|
CA2430039C
(en)
|
2000-11-28 |
2014-01-28 |
Medimmune, Inc. |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
WO2002043771A2
(en)
|
2000-12-01 |
2002-06-06 |
Cell Works Inc. |
Conjugates of glycosylated/galactosylated peptide
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
EP1683865A3
(en)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Mammalian proteins and in particular CD200
|
US20030044406A1
(en)
*
|
2001-03-02 |
2003-03-06 |
Christine Dingivan |
Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
CA2444483A1
(en)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Diagnostic imaging compositions, their methods of synthesis and use
|
WO2002092771A2
(en)
|
2001-05-11 |
2002-11-21 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
CN100594935C
(zh)
|
2001-05-25 |
2010-03-24 |
人体基因组科学有限公司 |
免疫特异性结合trail受体的抗体
|
WO2002096910A1
(en)
*
|
2001-05-31 |
2002-12-05 |
Medarex, Inc. |
Cytotoxins, prodrugs, linkers and stabilizers useful therefor
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
US7261875B2
(en)
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US20060046249A1
(en)
*
|
2002-01-18 |
2006-03-02 |
Fei Huang |
Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
|
US8435529B2
(en)
*
|
2002-06-14 |
2013-05-07 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
US8877901B2
(en)
*
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US8361464B2
(en)
*
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
JP2006509183A
(ja)
*
|
2002-03-05 |
2006-03-16 |
アクララ バイオサイエンシーズ, インコーポレイテッド |
膜結合増感剤を用いる多重分析
|
AU2003218456A1
(en)
*
|
2002-04-01 |
2003-10-20 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
CA2485548A1
(en)
|
2002-05-10 |
2004-02-19 |
Purdue Research Foundation |
Epha2 agonistic monoclonal antibodies and methods of use thereof
|
US20040229380A1
(en)
*
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
DE60329194D1
(de)
*
|
2002-07-25 |
2009-10-22 |
Aclara Biosciences Inc |
Nachweis der rezeptoroligomerisierung
|
JP2006508907A
(ja)
*
|
2002-07-26 |
2006-03-16 |
アクララ バイオサイエンシーズ, インコーポレイテッド |
親油性電気泳動プローブ
|
EP1545613B9
(en)
*
|
2002-07-31 |
2012-01-25 |
Seattle Genetics, Inc. |
Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
AU2003262650B2
(en)
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
US20040265315A1
(en)
*
|
2002-09-05 |
2004-12-30 |
Christine Dingivan |
Methods of preventing or treating T cell malignancies by administering CD2 antagonists
|
EP1551876B1
(en)
|
2002-10-16 |
2011-03-16 |
Purdue Pharma L.P. |
Antibodies that bind cell-associated ca 125/0722p and methods of use thereof
|
US20040091850A1
(en)
*
|
2002-11-08 |
2004-05-13 |
Travis Boone |
Single cell analysis of membrane molecules
|
JP4959136B2
(ja)
*
|
2002-12-13 |
2012-06-20 |
イミューノメディクス、インコーポレイテッド |
細胞内で開裂可能な結合を有する免疫接合体
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
MXPA05007615A
(es)
*
|
2003-01-21 |
2005-09-30 |
Bristol Myers Squibb Co |
Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
AU2004229501B2
(en)
|
2003-04-11 |
2011-08-18 |
Medimmune, Llc |
Recombinant IL-9 antibodies and uses thereof
|
US7402398B2
(en)
*
|
2003-07-17 |
2008-07-22 |
Monogram Biosciences, Inc. |
Measuring receptor homodimerization
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
AU2004286198C1
(en)
|
2003-08-18 |
2011-02-24 |
Medimmune, Llc |
Humanization of antibodies
|
WO2005045058A2
(en)
*
|
2003-10-27 |
2005-05-19 |
Monogram Biosciences, Inc. |
Detecting human anti-therapeutic antibodies
|
SI2489364T1
(sl)
|
2003-11-06 |
2015-04-30 |
Seattle Genetics, Inc. |
Monometilvalinske spojine, konjugirane s protitelesi
|
US7371381B2
(en)
*
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
GB0401008D0
(en)
*
|
2004-01-17 |
2004-02-18 |
Univ Manchester |
Drug delivery system
|
US20050175619A1
(en)
*
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
EP1786463A4
(en)
*
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
ANTIBODY AGAINST NOGO RECEPTOR
|
RU2402548C2
(ru)
*
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
EP1747021B1
(en)
*
|
2004-05-19 |
2015-09-09 |
E. R. Squibb & Sons, L.L.C. |
Self-immolative linkers and drug conjugates
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
EP3073267A1
(en)
|
2004-09-21 |
2016-09-28 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US7939267B2
(en)
*
|
2004-11-04 |
2011-05-10 |
Laboratory Corporation Of America Holdings |
Detection of activation of endothelial cells as surrogate marker for angiogenesis
|
WO2006071441A2
(en)
|
2004-11-30 |
2006-07-06 |
Curagen Corporation |
Antibodies directed to gpnmb and uses thereof
|
PT1851250E
(pt)
*
|
2005-02-18 |
2012-08-27 |
Medarex Inc |
Anticorpo monoclonal humano para o antigénio membranar específico da próstata (psma)
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
JP5153613B2
(ja)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
抗体のフレームワーク・シャッフル
|
ATE476655T1
(de)
*
|
2005-03-30 |
2010-08-15 |
Saladax Biomedical Inc |
Doxorubicin-immuntest
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
EP2301969B1
(en)
|
2005-05-06 |
2015-12-23 |
ZymoGenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
WO2007008604A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
CA2623652C
(en)
*
|
2005-09-26 |
2013-11-26 |
Medarex, Inc. |
Antibody-drug conjugates and methods of use
|
WO2007051081A1
(en)
|
2005-10-26 |
2007-05-03 |
Medarex, Inc. |
Methods and compounds for preparing cc-1065 analogs
|
ZA200804082B
(en)
|
2005-11-07 |
2010-02-24 |
Scripps Research Inst |
Compositions and methods for controlling tissue factor signaling specificity
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
WO2007106435A2
(en)
*
|
2006-03-10 |
2007-09-20 |
University Of California |
Cleavable vaccines compositions and methods of making and using the same
|
EP3026123A1
(en)
|
2006-04-27 |
2016-06-01 |
Klaritos, Inc. |
Method and kit for predicting antibody therapy
|
PT2029173T
(pt)
|
2006-06-26 |
2016-11-02 |
Macrogenics Inc |
Anticorpos específicos fc rib e seus métodos de uso
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EP2292663B1
(en)
|
2006-08-28 |
2013-10-02 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic human light-specific human monoclonal antibodies
|
WO2008028192A2
(en)
|
2006-09-01 |
2008-03-06 |
Zymogenetics, Inc. |
Variable region sequences of il-31 monoclonal antibodies and methods of use
|
CA2665826A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
US9090693B2
(en)
*
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
AR065404A1
(es)
|
2007-02-21 |
2009-06-03 |
Medarex Inc |
Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
|
JP5618549B2
(ja)
*
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
|
WO2008118970A2
(en)
|
2007-03-27 |
2008-10-02 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
EP2164868B1
(en)
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Engineered rabbit antibody variable domains and uses thereof
|
US20100291073A1
(en)
|
2007-05-14 |
2010-11-18 |
Medimmune, Llc |
Methods of reducing eosinophil levels
|
KR20100029764A
(ko)
*
|
2007-05-16 |
2010-03-17 |
케이티비 투머포슝스케쉘샤프트 엠비에이치 |
저점성 안트라사이클린 제제
|
UA103004C2
(ru)
|
2007-07-16 |
2013-09-10 |
Дженентек, Інк. |
Гуманизированное антитело против cd79b и иммуноконъюгаты и способы применения
|
TWI439286B
(zh)
|
2007-07-16 |
2014-06-01 |
Genentech Inc |
抗-cd79b抗體及免疫共軛物及使用方法
|
ES2609915T3
(es)
|
2007-08-14 |
2017-04-25 |
Ludwig Institute For Cancer Research Ltd. |
Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
|
ES2908934T3
(es)
|
2007-10-04 |
2022-05-04 |
Zymogenetics Inc |
ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
ME03057B
(me)
|
2007-12-07 |
2019-01-20 |
Zymogenetics Inc |
Molekuli humanizovanih antitela specifični za il-31
|
CA2711843C
(en)
*
|
2007-12-20 |
2018-11-13 |
Laboratory Corporation Of America Holdings |
Her-2 diagnostic methods
|
JP2011509675A
(ja)
|
2008-01-18 |
2011-03-31 |
メディミューン,エルエルシー |
部位特異的コンジュゲーションのためのシステイン操作抗体
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
MY159396A
(en)
|
2008-08-05 |
2016-12-30 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
ES2637411T3
(es)
|
2008-12-01 |
2017-10-13 |
Laboratory Corporation Of America Holdings |
Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
|
EP2387711B1
(en)
|
2009-01-15 |
2015-04-22 |
Laboratory Corporation of America Holdings |
Methods of determining patient response by measurement of her-3
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
US9028833B2
(en)
|
2012-12-13 |
2015-05-12 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
EP3903829B1
(en)
|
2009-02-13 |
2023-05-03 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
EP2437767B1
(en)
|
2009-06-01 |
2015-07-08 |
MedImmune, LLC |
Molecules with extended half-lives and uses thereof
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
ES2629167T3
(es)
|
2009-07-20 |
2017-08-07 |
Bristol-Myers Squibb Company |
Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas
|
EP2464657B1
(en)
|
2009-08-10 |
2015-04-01 |
MorphoSys AG |
Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
|
KR101778317B1
(ko)
|
2009-08-13 |
2017-09-13 |
얀센 백신스 앤드 프리벤션 비.브이. |
사람 호흡기 세포융합 바이러스(rsv)에 대한 항체 및 이용 방법
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
MY173390A
(en)
|
2009-10-23 |
2020-01-22 |
Takeda Pharmaceuticals Co |
Anti-gcc antibody molecules and related compositions and methods
|
PL2510011T3
(pl)
|
2009-12-09 |
2015-02-27 |
Inst Nat Sante Rech Med |
Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
|
KR101510413B1
(ko)
|
2010-02-08 |
2015-04-08 |
어젠시스 인코포레이티드 |
161p2f10b 단백질에 결합하는 항체 약물 컨쥬게이트
|
EP2552967A4
(en)
|
2010-04-02 |
2014-10-08 |
Amunix Operating Inc |
BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
|
ES2659406T3
(es)
|
2010-05-06 |
2018-03-15 |
Novartis Ag |
Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
|
EA201291181A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
AR082149A1
(es)
|
2010-07-09 |
2012-11-14 |
Calmune Corp |
Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
|
KR20190104442A
(ko)
|
2010-07-09 |
2019-09-09 |
바이오버라티브 테라퓨틱스 인크. |
인자 ix 폴리펩티드 및 이들의 사용 방법
|
US8871744B2
(en)
|
2010-07-21 |
2014-10-28 |
B & G Partyers, LLC |
Compounds and methods for selectively targeting tumor-associated mucins
|
CN103052649B
(zh)
|
2010-07-29 |
2015-12-16 |
Xencor公司 |
具有修改的等电点的抗体
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
UA114883C2
(uk)
|
2010-08-20 |
2017-08-28 |
Новартіс Аг |
Антитіло до рецептора епідермального фактора росту-3 (her3)
|
RU2013113638A
(ru)
|
2010-08-27 |
2014-10-10 |
Стем Сентркс, Инк. |
МОДУЛЯТОРЫ БЕЛКА Notum И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2012031273A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
LT2621526T
(lt)
|
2010-09-29 |
2018-09-25 |
Agensys, Inc. |
Antikūno-vaisto konjugatai (adc), kurie jungiasi prie 191p4d12 baltymų
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
DK2635607T3
(da)
|
2010-11-05 |
2019-11-18 |
Zymeworks Inc |
Stabilt heterodimert antistofdesign med mutationer i fc-domænet
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
BR112013013781A2
(pt)
|
2010-12-06 |
2016-09-13 |
Seattle Genetics Inc |
anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
|
RU2592672C9
(ru)
|
2010-12-08 |
2016-11-27 |
СтемСентРкс, Инк. |
Новые модуляторы и способы их применения
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
ES2701929T3
(es)
|
2011-05-19 |
2019-02-26 |
Laboratory Corp America Holdings |
Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer
|
CN106279418A
(zh)
|
2011-05-27 |
2017-01-04 |
葛兰素集团有限公司 |
Bcma(cd269/tnfrsf17)结合蛋白
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
WO2013043071A1
(en)
|
2011-09-23 |
2013-03-28 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Modified albumin-binding domains and uses thereof to improve pharmacokinetics
|
CA2851534C
(en)
|
2011-10-10 |
2023-02-14 |
Xencor, Inc. |
A method for purifying antibodies
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
CN103071159B
(zh)
*
|
2011-10-25 |
2014-10-15 |
天津药物研究院 |
一种阿霉素-多肽复合物、药物组合物的制备方法和应用
|
EP2773667A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
WO2013067054A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
EP2773669B1
(en)
|
2011-11-04 |
2018-03-28 |
Novartis AG |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
HRP20211773T1
(hr)
|
2011-11-04 |
2022-03-04 |
Zymeworks Inc. |
Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
|
JP2015505828A
(ja)
|
2011-12-02 |
2015-02-26 |
イーライ リリー アンド カンパニー |
抗グルカゴン抗体およびその使用
|
BR112014013412A8
(pt)
|
2011-12-05 |
2021-06-08 |
Novartis Ag |
anticorpos para o receptor 3 do fator de crescimento epidérmico (her3), e seus usos
|
EA201491107A1
(ru)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
|
ES2728278T3
(es)
|
2011-12-21 |
2019-10-23 |
Novartis Ag |
Composiciones que comprenden anticuerpos dirigidos al factor P y C5
|
EP3446707A1
(en)
|
2011-12-22 |
2019-02-27 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
JP2015505537A
(ja)
|
2012-01-20 |
2015-02-23 |
シー レーン バイオテクノロジーズ, エルエルシー |
結合分子コンジュゲート
|
ES2645272T3
(es)
|
2012-02-24 |
2017-12-04 |
Abbvie Stemcentrx Llc |
Moduladores de DLL3 y procedimientos de utilización
|
EP2817339B1
(en)
|
2012-02-24 |
2019-05-15 |
AbbVie Stemcentrx LLC |
Anti sez6 antibodies and methods of use
|
US10172953B2
(en)
|
2012-02-27 |
2019-01-08 |
Amunix Operating Inc. |
XTEN conjugate compositions and methods of making same
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
JP6351572B2
(ja)
|
2012-05-10 |
2018-07-04 |
ザイムワークス,インコーポレイテッド |
Fcドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
|
JP6423340B2
(ja)
|
2012-05-15 |
2018-11-14 |
シアトル ジェネティクス,インコーポレイティド |
自己安定化リンカー結合体
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
CA2880007C
(en)
|
2012-07-25 |
2021-12-28 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
MX364265B
(es)
|
2012-08-23 |
2019-04-17 |
Agensys Inc |
Conjugados de anticuerpo farmaco (adc) que enlazan a las proteinas 158p1d7.
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
WO2014053479A1
(en)
|
2012-10-02 |
2014-04-10 |
Roche Diagnostics Gmbh |
Methods of specifically releasing a sub-group of objects
|
AU2013329311A1
(en)
|
2012-10-09 |
2015-04-30 |
Igenica Biotherapeutics, Inc. |
Anti-C16orf54 antibodies and methods of use thereof
|
EP2922818B1
(en)
|
2012-11-24 |
2018-09-05 |
Hangzhou Dac Biotech Co., Ltd |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
HUE053669T2
(hu)
|
2012-12-05 |
2021-07-28 |
Novartis Ag |
Készítmények és eljárások EPO-t célzó antitestekre
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
CN104995303A
(zh)
|
2012-12-18 |
2015-10-21 |
诺华股份有限公司 |
利用结合乙酰透明质酸的肽标签的组合物和方法
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
SI2943511T1
(sl)
|
2013-01-14 |
2020-01-31 |
Xencor, Inc. |
Novi heterodimerni proteini
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CA2895284A1
(en)
|
2013-02-07 |
2014-08-14 |
Immunomedics, Inc. |
Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
|
PT2958944T
(pt)
|
2013-02-22 |
2019-06-27 |
Medimmune Ltd |
Conjugados de anticorpos anti-dll3 e pbd e suas utilizações
|
SG11201506088RA
(en)
|
2013-03-11 |
2015-09-29 |
Genzyme Corp |
Hyperglycosylated binding polypeptides
|
WO2014159562A1
(en)
|
2013-03-14 |
2014-10-02 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
SG10201707600XA
(en)
|
2013-03-15 |
2017-11-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
PL2968440T3
(pl)
|
2013-03-15 |
2019-12-31 |
Zymeworks Inc. |
Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
KR102211176B1
(ko)
|
2013-03-15 |
2021-02-01 |
젠코어 인코포레이티드 |
이형이량체 단백질
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
CN105264382A
(zh)
|
2013-04-05 |
2016-01-20 |
美国控股实验室公司 |
基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法
|
NZ714765A
(en)
|
2013-06-06 |
2021-12-24 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
UA118198C2
(uk)
|
2013-08-01 |
2018-12-10 |
Ейдженсіс, Інк. |
Кон'югат антитіло-лікарський засіб, який зв'язується з білком cd37
|
EP3041507B1
(en)
|
2013-08-26 |
2021-06-30 |
BioNTech Research and Development, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewis a
|
AU2014312310A1
(en)
|
2013-08-28 |
2016-04-07 |
Abbvie Stemcentrx Llc |
Novel SEZ6 modulators and methods of use
|
SG11201601424PA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Site-specific antibody conjugation methods and compositions
|
KR102357173B1
(ko)
|
2013-10-11 |
2022-01-27 |
옥스포드 바이오테라퓨틱스 리미티드 |
암을 치료하기 위한 ly75에 대한 접합 항체
|
EP3620470B1
(en)
|
2013-10-11 |
2023-07-26 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Tem8 antibodies and their use
|
PL3057585T3
(pl)
|
2013-10-15 |
2020-12-28 |
Seagen Inc. |
Pegylowane elementy lek-łącznik do poprawy farmakokinetyki koniugatu ligand-lek
|
JP2016540826A
(ja)
|
2013-11-04 |
2016-12-28 |
ファイザー・インク |
抗efna4抗体−薬物コンジュゲート
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
EP3074036B1
(en)
|
2013-11-25 |
2019-09-18 |
Seattle Genetics, Inc. |
Preparing antibodies from cho cell cultures for conjugation
|
KR102384740B1
(ko)
|
2013-12-27 |
2022-04-07 |
자임워크스 인코포레이티드 |
약물 접합체를 위한 설폰아마이드-함유 연결 시스템
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2015103989A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for immunotherapy
|
PL3097122T3
(pl)
|
2014-01-24 |
2020-10-19 |
Ngm Biopharmaceuticals, Inc. |
Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
|
CR20160437A
(es)
|
2014-02-21 |
2017-02-20 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para uso en el tratamiento contra melanoma
|
CN114262344A
(zh)
|
2014-02-28 |
2022-04-01 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
CN116333148A
(zh)
|
2014-03-19 |
2023-06-27 |
建新公司 |
靶向模块的位点特异性糖工程化
|
PE20161211A1
(es)
|
2014-03-21 |
2016-11-27 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
|
EP3122376A4
(en)
|
2014-03-27 |
2017-12-20 |
The Brigham and Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
SG10202008629XA
(en)
|
2014-03-28 |
2020-10-29 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
MX2016012873A
(es)
|
2014-04-04 |
2017-03-07 |
Bionomics Inc |
Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
|
US10329556B2
(en)
|
2014-05-13 |
2019-06-25 |
Bioatla, Llc |
Conditionally active biological proteins
|
EP3142700B1
(en)
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
CA3121083C
(en)
|
2014-06-04 |
2023-08-15 |
Biontech Research And Development, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
EP3797768A1
(en)
|
2014-06-23 |
2021-03-31 |
Placon Therapeutics, Inc. |
Maleimide-functionalised platinum for use in the treatment of cancer
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
SG11201700365TA
(en)
|
2014-07-24 |
2017-02-27 |
Genentech Inc |
Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
|
WO2016014984A1
(en)
|
2014-07-24 |
2016-01-28 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
ES2906216T3
(es)
|
2014-08-07 |
2022-04-13 |
Novartis Ag |
Anticuerpos de 4 similar a la angiopoyetina y métodos de uso
|
TW201613977A
(en)
|
2014-08-07 |
2016-04-16 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
EP3189152A4
(en)
|
2014-09-03 |
2018-04-04 |
BioAtla LLC |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
HUE057768T2
(hu)
|
2014-09-17 |
2022-06-28 |
Zymeworks Inc |
Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei
|
RS60349B8
(sr)
|
2014-09-23 |
2022-10-31 |
Hoffmann La Roche |
Postupak upotrebe anti-cd79b imunokonjugata
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
US10064952B2
(en)
|
2014-10-09 |
2018-09-04 |
Genzyme Corporation |
Glycoengineered antibody drug conjugates
|
BR112017010498A2
(pt)
|
2014-11-19 |
2017-12-26 |
Axon Neuroscience Se |
anticorpos tau humanizados em doença de alzheimer
|
NZ732144A
(en)
|
2014-11-26 |
2020-04-24 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
US10766959B2
(en)
|
2014-12-11 |
2020-09-08 |
Pierre Fabre Medicament |
Anti-C10ORF54 antibodies and uses thereof
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
PL3265123T3
(pl)
|
2015-03-03 |
2023-03-13 |
Kymab Limited |
Przeciwciała, zastosowania i sposoby
|
US10472395B2
(en)
|
2015-03-05 |
2019-11-12 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
AR103896A1
(es)
|
2015-03-09 |
2017-06-14 |
Agensys Inc |
Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
EP3291836A4
(en)
|
2015-05-06 |
2018-11-14 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
CA2982237A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
WO2016201394A1
(en)
|
2015-06-12 |
2016-12-15 |
Miltenyi Biotec Technology, Inc. |
Method to treat cancer with engineered t-cells
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
DK3316909T3
(da)
|
2015-06-30 |
2023-11-13 |
Seagen Inc |
Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
|
WO2015151081A2
(en)
|
2015-07-12 |
2015-10-08 |
Suzhou M-Conj Biotech Co., Ltd |
Bridge linkers for conjugation of a cell-binding molecule
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
JP6940479B2
(ja)
|
2015-08-03 |
2021-09-29 |
ノバルティス アーゲー |
Fgf21関連障害を処置する方法
|
MY186352A
(en)
|
2015-09-09 |
2021-07-15 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
EP3347377B1
(en)
|
2015-09-09 |
2021-02-17 |
Novartis AG |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
US10799580B2
(en)
|
2015-09-09 |
2020-10-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expression vector delivery system and use thereof for inducing an immune response
|
AR106184A1
(es)
|
2015-09-29 |
2017-12-20 |
Celgene Corp |
Proteínas de unión a pd-1 y sus métodos de uso
|
WO2017062748A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
JP6821688B2
(ja)
|
2015-10-09 |
2021-01-27 |
ミルテニー・バイオテク・テクノロジー・インコーポレイテッドMiltenyi Biotec Technology, Inc. |
キメラ抗原受容体および使用方法
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
CN115521374A
(zh)
|
2015-11-02 |
2022-12-27 |
生物蛋白有限公司 |
条件活性多肽
|
KR20210016479A
(ko)
|
2015-12-04 |
2021-02-15 |
노파르티스 아게 |
항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
US20170198040A1
(en)
|
2015-12-18 |
2017-07-13 |
Novartis Ag |
ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
|
EP3405492B1
(en)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
WO2017147597A1
(en)
|
2016-02-27 |
2017-08-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide vaccines comprising self-assembling polymer nanoparticles
|
PE20181953A1
(es)
|
2016-03-02 |
2018-12-17 |
Eisai Randd Man Co Ltd |
Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
WO2017161030A1
(en)
|
2016-03-15 |
2017-09-21 |
Laboratory Corporation Of America Holdings |
Methods of assessing protein interactions between cells
|
CA3018081A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINE LINKS AND INTERMEDIATES THEREOF
|
JP2019522960A
(ja)
|
2016-04-21 |
2019-08-22 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規の抗bmpr1b抗体及び使用方法
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
EP3448887A1
(en)
|
2016-04-27 |
2019-03-06 |
Novartis AG |
Antibodies against growth differentiation factor 15 and uses thereof
|
CA3016917A1
(en)
|
2016-04-27 |
2017-11-02 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
WO2017214322A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CA3027046A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
SG10201914119TA
(en)
|
2016-06-08 |
2020-02-27 |
Abbvie Inc |
Anti-b7-h3 antibodies and antibody drug conjugates
|
US20200338209A1
(en)
|
2016-06-08 |
2020-10-29 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
KR20230054508A
(ko)
|
2016-06-14 |
2023-04-24 |
젠코어 인코포레이티드 |
이중특이적 체크포인트 억제제 항체
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
US11560356B2
(en)
|
2016-06-29 |
2023-01-24 |
The Regents Of The University Of California |
Compounds and compositions for the treatment of cancer
|
WO2018005697A1
(en)
|
2016-06-29 |
2018-01-04 |
The Regents Of The University Of California |
Antibodies specific to sonic hedgehog and method of use thereof
|
EP3481866B1
(en)
|
2016-07-06 |
2024-07-24 |
Bristol-Myers Squibb Company |
Combination of tim-4 antagonist and pd-1 antagonist and methods of use
|
SG11201900699QA
(en)
|
2016-08-09 |
2019-02-27 |
Seattle Genetics Inc |
Drug conjugates with self-stabilizing linkers having improved physiochemical properties
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3507304B1
(en)
|
2016-09-02 |
2024-04-03 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
BR112019004733A2
(pt)
|
2016-09-19 |
2019-05-28 |
Celgene Corp |
métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
JP7273453B2
(ja)
|
2016-10-14 |
2023-05-15 |
ゼンコア インコーポレイテッド |
IL-15/IL-15RアルファFc融合タンパク質およびPD-1抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
KR102459469B1
(ko)
|
2016-11-14 |
2022-10-26 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
EP3559047A1
(en)
|
2016-12-23 |
2019-10-30 |
Novartis AG |
Factor xi antibodies and methods of use
|
EP3558370A2
(en)
|
2016-12-23 |
2019-10-30 |
Novartis AG |
Methods of treatment with anti-factor xi/xia antibodies
|
CN117946283A
(zh)
|
2017-01-09 |
2024-04-30 |
莱蒂恩技术公司 |
用于用抗间皮素免疫治疗癌症的组合物和方法
|
CN110300765B
(zh)
|
2017-01-24 |
2024-08-23 |
依奈特制药公司 |
Nkp46结合剂
|
EP3577138A1
(en)
|
2017-02-06 |
2019-12-11 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
US10899844B2
(en)
|
2017-02-08 |
2021-01-26 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
MX2019010769A
(es)
|
2017-03-24 |
2019-12-11 |
Seattle Genetics Inc |
Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
|
WO2018175988A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
US10918734B2
(en)
|
2017-03-27 |
2021-02-16 |
Immunomedics, Inc. |
Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
US20200054741A1
(en)
|
2017-04-04 |
2020-02-20 |
Avidea Technologies, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
CN110730908A
(zh)
|
2017-04-07 |
2020-01-24 |
朱诺治疗学股份有限公司 |
表达前列腺特异性膜抗原(psma)或其修饰形式的工程化细胞及相关方法
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
AU2018259856A1
(en)
|
2017-04-28 |
2019-11-14 |
Ajinomoto Co., Inc. |
Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
CN110662762A
(zh)
|
2017-05-24 |
2020-01-07 |
诺华股份有限公司 |
抗体细胞因子移植蛋白和用于治疗癌症的方法
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
EP3661964A1
(en)
|
2017-07-31 |
2020-06-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
EP3668600B1
(en)
|
2017-08-10 |
2024-05-15 |
Abionyx Pharma SA |
Cargomers
|
JP7035170B2
(ja)
|
2017-09-15 |
2022-03-14 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd19免疫療法によりがんを処置するための組成物および方法
|
CN111630069B
(zh)
|
2017-10-13 |
2024-05-31 |
勃林格殷格翰国际有限公司 |
针对Thomsen-nouvelle(Tn)抗原的人抗体
|
CN111629735B
(zh)
|
2017-10-16 |
2024-05-17 |
莱蒂恩技术公司 |
用于用抗cd22免疫治疗来治疗癌症的组合物和方法
|
CN111542344A
(zh)
|
2017-10-23 |
2020-08-14 |
马布林克生物科学公司 |
包含单分子量聚肌氨酸的配体-药物-缀合物
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CN111757892A
(zh)
|
2017-12-01 |
2020-10-09 |
西雅图基因公司 |
用于治疗乳腺癌的人源化抗liv1抗体
|
CN111448213A
(zh)
|
2017-12-01 |
2020-07-24 |
西雅图基因公司 |
Cd47抗体及其用于治疗癌症的用途
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
US10894819B2
(en)
|
2017-12-20 |
2021-01-19 |
Lentigen Technology, Inc. |
Compositions and methods for treating HIV/AIDS with immunotherapy
|
WO2019129054A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
TW202330621A
(zh)
|
2018-02-01 |
2023-08-01 |
大陸商信達生物製藥(蘇州)有限公司 |
全人源的抗b細胞成熟抗原(bcma)單鏈抗體及其應用
|
WO2019180150A1
(en)
|
2018-03-22 |
2019-09-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
KR20200135841A
(ko)
|
2018-03-23 |
2020-12-03 |
시애틀 지네틱스, 인크. |
고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
SG11202008098TA
(en)
|
2018-03-28 |
2020-10-29 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating alzheimer's disease
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
EP3796943A2
(en)
|
2018-05-22 |
2021-03-31 |
Avidea Technologies, Inc. |
Improved methods of manufacturing peptide-based vaccines
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
MX2020012997A
(es)
|
2018-06-01 |
2021-03-29 |
Eisai R&D Man Co Ltd |
Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
|
KR20210020015A
(ko)
|
2018-06-14 |
2021-02-23 |
아지노모토 가부시키가이샤 |
항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
|
JP7413999B2
(ja)
|
2018-06-14 |
2024-01-16 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
BR112020026724A2
(pt)
|
2018-07-02 |
2021-03-30 |
Amgen Inc. |
Proteína de ligação ao antígeno anti-steap1
|
CA3106418A1
(en)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Receptor for vista
|
WO2020023561A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
CN113260630B
(zh)
|
2018-09-20 |
2024-05-24 |
莱蒂恩技术公司 |
用于用抗cd123免疫治疗来治疗癌症的组合物和方法
|
AU2019350865A1
(en)
|
2018-09-26 |
2021-04-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with Anti-CD19/CD22 immunotherapy
|
US11358999B2
(en)
|
2018-10-03 |
2022-06-14 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
AU2019355926A1
(en)
|
2018-10-03 |
2021-04-22 |
Barinthus Biotherapeutics North America, Inc. |
Aromatic ring substituted amphiphilic polymers as drug delivery systems
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
CN113227124A
(zh)
|
2018-10-31 |
2021-08-06 |
味之素株式会社 |
具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
|
CN113412119A
(zh)
|
2018-11-30 |
2021-09-17 |
莱蒂恩技术公司 |
用于用抗cd38免疫治疗来治疗癌症的组合物和方法
|
JP2022512401A
(ja)
|
2018-12-13 |
2022-02-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
|
SG11202107551WA
(en)
|
2019-02-05 |
2021-08-30 |
Seagen Inc |
Anti-cd228 antibodies and antibody-drug conjugates
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
CA3132660A1
(en)
|
2019-03-06 |
2020-09-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
AU2020241896A1
(en)
|
2019-03-20 |
2021-09-23 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
CN114206934A
(zh)
|
2019-03-20 |
2022-03-18 |
加利福尼亚大学董事会 |
密封蛋白-6双特异性抗体
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
US20230026627A1
(en)
|
2019-04-17 |
2023-01-26 |
Vaccitech North America, Inc. |
Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery
|
JP2022530026A
(ja)
|
2019-04-24 |
2022-06-27 |
ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アマトキシン抗体薬物複合体及びその使用
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
JOP20210309A1
(ar)
|
2019-05-21 |
2023-01-30 |
Novartis Ag |
جزيئات ربط بـ cd19 واستخدامتها
|
AU2020283027A1
(en)
|
2019-05-30 |
2021-12-23 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-BCMA immunotherapy
|
WO2020247572A1
(en)
|
2019-06-05 |
2020-12-10 |
Seattle Genetics, Inc. |
Masked antibody formulations
|
TW202112801A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
純化遮蔽抗體之方法
|
KR20220031054A
(ko)
|
2019-07-02 |
2022-03-11 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Egfrviii에 결합하는 단일클론 항체 및 이의 용도
|
MX2022000853A
(es)
|
2019-07-22 |
2022-03-17 |
Seagen Inc |
Anticuerpos anti-liv1 humanizados para el tratamiento de cancer.
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
AR120147A1
(es)
|
2019-10-04 |
2022-02-02 |
Seattle Genetics Inc |
Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
|
EP4017542A1
(en)
|
2019-10-04 |
2022-06-29 |
Tae Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
AU2021205893A1
(en)
|
2020-01-08 |
2022-06-23 |
Synthis Therapeutics, Inc. |
ALK5 inhibitor conjugates and uses thereof
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
US20230242647A1
(en)
|
2020-05-01 |
2023-08-03 |
Novartis Ag |
Engineered immunoglobulins
|
EP4143224A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Immunoglobulin variants
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
TW202210517A
(zh)
|
2020-06-05 |
2022-03-16 |
日商衛材R&D企管股份有限公司 |
抗bcma抗體-藥物軛合物及其使用方法
|
EP4163294A4
(en)
|
2020-06-09 |
2024-07-24 |
Ajinomoto Kk |
MODIFIED FERRITIN AND METHOD FOR PRODUCING SAME
|
CN116829581A
(zh)
|
2020-06-22 |
2023-09-29 |
莱蒂恩技术公司 |
用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
|
JP2023537714A
(ja)
|
2020-08-04 |
2023-09-05 |
シージェン インコーポレイテッド |
抗cd228抗体及び抗体薬物コンジュゲート
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
AU2021347147A1
(en)
|
2020-09-22 |
2023-05-18 |
Barinthus Biotherapeutics North America, Inc. |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
US20220112274A1
(en)
|
2020-09-28 |
2022-04-14 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
AU2021354095A1
(en)
|
2020-10-01 |
2023-06-08 |
Abionyx Pharma Sa |
Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
|
WO2022086853A1
(en)
|
2020-10-19 |
2022-04-28 |
Avidea Technologies, Inc. |
Star polymer drug conjugates
|
WO2022084325A1
(en)
|
2020-10-20 |
2022-04-28 |
Institut Curie |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
EP4240397A1
(en)
|
2020-11-05 |
2023-09-13 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
CA3208290A1
(en)
|
2021-01-18 |
2022-07-21 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained by using the same
|
WO2022154116A1
(ja)
|
2021-01-18 |
2022-07-21 |
味の素株式会社 |
化合物またはその塩、およびそれらにより得られる抗体
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
WO2022177993A1
(en)
|
2021-02-16 |
2022-08-25 |
Vaccitech North America, Inc. |
Self-assembling nanoparticles based on amphiphilic peptides
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
CA3212822A1
(en)
|
2021-03-11 |
2022-09-15 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained by using the same
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
EP4310096A1
(en)
|
2021-03-16 |
2024-01-24 |
Ajinomoto Co., Inc. |
Complex or salt thereof, and method for manufacturing same
|
KR20230158005A
(ko)
|
2021-03-18 |
2023-11-17 |
씨젠 인크. |
생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
|
BR112023018189A2
(pt)
|
2021-03-19 |
2023-10-24 |
Heidelberg Pharma Res Gmbh |
Conjugados de anticorpos de amatoxina específicos de linfócitos b, composição famacêutica e uso relacionados
|
CA3213985A1
(en)
|
2021-03-30 |
2022-10-06 |
Chang Sik Park |
Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
|
AU2022253902A1
(en)
|
2021-04-10 |
2023-11-02 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
CA3216226A1
(en)
|
2021-04-15 |
2022-10-20 |
Abionyx Pharma Sa |
Use of lipid binding protein-based complexes in organ preservation solutions
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Cd70結合劑、其結合物及其使用方法
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023288236A1
(en)
|
2021-07-14 |
2023-01-19 |
Seagen Inc. |
Antibody masking domains
|
EP4405387A1
(en)
|
2021-09-24 |
2024-07-31 |
Seagen Inc. |
Improved antibody masking domains
|
CA3234692A1
(en)
|
2021-09-30 |
2023-04-06 |
Ajinomoto Co., Inc. |
Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
CA3238167A1
(en)
|
2021-11-19 |
2023-05-25 |
Maria Leia Smith |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
CN116284385A
(zh)
|
2021-12-07 |
2023-06-23 |
信达细胞制药(苏州)有限公司 |
靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
|
AU2023206045A1
(en)
|
2022-01-07 |
2024-08-22 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
AU2023229967A1
(en)
|
2022-03-11 |
2024-08-08 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
WO2023194539A1
(en)
|
2022-04-07 |
2023-10-12 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index of amatoxin-antibody conjugates
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
WO2024092030A1
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Self-assembling nanoparticles
|
WO2024092028A2
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Combination treatment regimes for treating cancer
|
US20240165257A1
(en)
|
2022-11-01 |
2024-05-23 |
Heidelberg Pharma Research Gmbh |
Anti-gucy2c antibody and uses thereof
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
EP4382120A1
(en)
|
2022-12-05 |
2024-06-12 |
Institut Regional du Cancer de Montpellier |
Anti-slc1a4 monoclonal antibodies and uses thereof
|
WO2024121632A1
(en)
|
2022-12-09 |
2024-06-13 |
Crispr Therapeutics Ag |
Use of anti-cd117 antibody drug conjugate (adc)
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
WO2024170660A1
(en)
|
2023-02-16 |
2024-08-22 |
Astrazeneca Ab |
Combination therapies for treatment of cancer with therapeutic binding molecules
|